Cytotoxic Natural Killer Subpopulations as a Prognostic Factor of Malignant Pleural Effusion.
Aged
Aged, 80 and over
Biomarkers
/ blood
CD56 Antigen
/ blood
CD57 Antigens
/ blood
Female
GPI-Linked Proteins
/ blood
Humans
Immunophenotyping
/ methods
Killer Cells, Natural
/ immunology
Lymphocyte Subsets
/ immunology
Male
Middle Aged
Phenotype
Pleural Effusion, Malignant
/ blood
Predictive Value of Tests
Prognosis
Prospective Studies
Receptors, IgG
/ blood
Biomarker
Cancer
Diagnosis
Flow cytometry
Natural killer cells
Pleural effusion
Prognosis
Journal
Lung
ISSN: 1432-1750
Titre abrégé: Lung
Pays: United States
ID NLM: 7701875
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
11
04
2018
accepted:
29
11
2018
pubmed:
14
12
2018
medline:
16
1
2020
entrez:
8
12
2018
Statut:
ppublish
Résumé
Malignant pleural effusion (MPE) is a sign of advanced disease of poor prognosis. As natural killer (NK) cells are involved in the first line of tumour defence, we aimed to validate a new diagnostic and prognostic indicator for MPE based on NK subpopulations of pleural fluid (PF) and peripheral blood (PB). NK subpopulations were determined in PF and PB in 71 patients with malignant, paramalignant or benign pleural effusion. The receiver operating characteristic (ROC) curves, Kaplan-Meier, multivariable Cox model and decision trees created with the CHAID (Chi-square automatic interaction detector) methodology were employed. We demonstrated that the PF/PB ratios of the CD56 bright CD16- and CD56 dim CD16- NK subpopulations were higher (p = 0.013 and p = 0.003, respectively) in MPEs and paramalignant pleural effusions (PPEs) than in benign ones, with an AUC of 0.757 and 0.741, respectively. The PF/PB ratio of CD16+ NK and CD57+ NK obtained a higher hazard ratio (HR) in the crude Cox's regression analysis. In the adjusted Cox's regression analysis, the PF/PB ratio of CD16+ NK gave the highest HR (HR 6.1 [1.76-21.1]) (p = 0.004). In the decision tree created for the MPE prognosis, we observed that the main predictor variable among the studied clinical, radiological, and analytical variables was lung mass, and that 92.9% of the patients who survived had a PF/PB ratio of the CD56 dim CD16+ NK subpopulation ≤ 0.43. Our data suggest that both the PF/PB ratios of cytotoxic subpopulations CD57+ NK and CD16+ NK are useful as a prognostic factor of MPE. Other subpopulations (CD56 bright CD16- and CD56 dim CD16- NK) could help to diagnose MPE.
Sections du résumé
BACKGROUND
Malignant pleural effusion (MPE) is a sign of advanced disease of poor prognosis. As natural killer (NK) cells are involved in the first line of tumour defence, we aimed to validate a new diagnostic and prognostic indicator for MPE based on NK subpopulations of pleural fluid (PF) and peripheral blood (PB).
METHODS
NK subpopulations were determined in PF and PB in 71 patients with malignant, paramalignant or benign pleural effusion. The receiver operating characteristic (ROC) curves, Kaplan-Meier, multivariable Cox model and decision trees created with the CHAID (Chi-square automatic interaction detector) methodology were employed.
RESULTS
We demonstrated that the PF/PB ratios of the CD56 bright CD16- and CD56 dim CD16- NK subpopulations were higher (p = 0.013 and p = 0.003, respectively) in MPEs and paramalignant pleural effusions (PPEs) than in benign ones, with an AUC of 0.757 and 0.741, respectively. The PF/PB ratio of CD16+ NK and CD57+ NK obtained a higher hazard ratio (HR) in the crude Cox's regression analysis. In the adjusted Cox's regression analysis, the PF/PB ratio of CD16+ NK gave the highest HR (HR 6.1 [1.76-21.1]) (p = 0.004). In the decision tree created for the MPE prognosis, we observed that the main predictor variable among the studied clinical, radiological, and analytical variables was lung mass, and that 92.9% of the patients who survived had a PF/PB ratio of the CD56 dim CD16+ NK subpopulation ≤ 0.43.
CONCLUSIONS
Our data suggest that both the PF/PB ratios of cytotoxic subpopulations CD57+ NK and CD16+ NK are useful as a prognostic factor of MPE. Other subpopulations (CD56 bright CD16- and CD56 dim CD16- NK) could help to diagnose MPE.
Identifiants
pubmed: 30523401
doi: 10.1007/s00408-018-0186-7
pii: 10.1007/s00408-018-0186-7
doi:
Substances chimiques
Biomarkers
0
CD56 Antigen
0
CD57 Antigens
0
FCGR3B protein, human
0
GPI-Linked Proteins
0
NCAM1 protein, human
0
Receptors, IgG
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
53-60Références
BMC Cancer. 2013 Jul 02;13:324
pubmed: 23816056
Am J Respir Crit Care Med. 2000 Nov;162(5):1987-2001
pubmed: 11069845
Acta Cytol. 1996 Nov-Dec;40(6):1240-5
pubmed: 8960035
Arch Immunol Ther Exp (Warsz). 1993;41(1):51-6
pubmed: 8239908
Diagn Cytopathol. 1999 Jul;21(1):18-21
pubmed: 10405802
Respiration. 2013;86(3):216-23
pubmed: 23258197
Diagn Cytopathol. 2000 Jun;22(6):347-50
pubmed: 10820527
Cytometry B Clin Cytom. 2013 May;84(3):202-4
pubmed: 23281059
J Leukoc Biol. 2010 Jan;87(1):107-16
pubmed: 19880576
Cytometry B Clin Cytom. 2009 May;76(3):213-7
pubmed: 18803280
Immunology. 2009 Apr;126(4):458-65
pubmed: 19278419
Eur J Cancer. 2011 Jan;47(2):296-304
pubmed: 20932742
Thorax. 2010 Aug;65 Suppl 2:ii32-40
pubmed: 20696691
Tumour Biol. 1998;19(3):196-204
pubmed: 9591046
Eur J Immunol. 2013 Feb;43(2):550-61
pubmed: 23192659
Arch Bronconeumol. 2014 Jun;50(6):235-49
pubmed: 24698396
Am J Clin Pathol. 2006 Mar;125(3):451-8
pubmed: 16613351
Clin Cancer Res. 2004 Apr 15;10(8):2600-8
pubmed: 15102661
Arch Bronconeumol. 2006 Jul;42(7):349-72
pubmed: 16945266
Blood. 2010 Nov 11;116(19):3865-74
pubmed: 20733159
Front Immunol. 2013 Dec 09;4:422
pubmed: 24367364
Int J Cancer. 2011 Jun 1;128(11):2663-72
pubmed: 20715106